Literature DB >> 12621061

Signal transduction pathways regulated by prolactin and Src result in different conformations of activated Stat5b.

Elena B Kabotyanski1, Jeffrey M Rosen.   

Abstract

Stat5 is activated by a broad spectrum of cytokines, as well as non-receptor tyrosine kinases, such as Src. In this study, the DNA binding properties of the two closely related Stat5 proteins, Stat5a and Stat5b, induced either by prolactin (Prl) or by Src were analyzed by electrophoretic mobility shift assays using several different Stat5 binding sites. Src-induced Stat5b-DNA binding complexes consistently displayed a slightly faster mobility than those induced by Prl, as well as differences in their ability to be supershifted by anti-Stat5 antibodies. IP-Westerns performed using specific antibodies directed at the N and C termini of Stat5b suggested that depending on the activating stimulus, Stat5b exhibited different conformations, which influenced antibody accessibility at its C terminus. These conformational differences may in part be due to differential effects of Prl and Src on Stat5b tyrosine phosphorylation, since Src induced several additional sites of tyrosine phosphorylation of Stat5b at residues other than Tyr-699, including Tyr-724 and Tyr-679. The latter Tyr-679 is conserved in all mammalian Stat5bs, but is not present in Stat5a. A Stat 5bY679F mutant induced by Src kinase exhibited an altered pattern of nuclear localization as compared with wild-type Stat5b. Furthermore, this mutation inhibited v-Src-induced cyclin D1-luciferase reporter activity in transient transfection assays performed in Stat5a/b-deficient MEFs, suggesting that Tyr-679 phosphorylation may play a role in v-Src induced proliferation. Thus, depending on the signal transduction pathway responsible for activation, different conformations of activated Stat5 may result in selective biological responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621061     DOI: 10.1074/jbc.M301578200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Synergistic effect of EMS1-shRNA and sorafenib on proliferation, migration, invasion and endocytosis of SMMC-7721.

Authors:  Jiaming Zhou; Li Chen; Yixin Zhang; Yuanyuan Wu; Guilan Wang; Song He; Zhongying Guo; Yingze Wei
Journal:  J Mol Histol       Date:  2013-10-15       Impact factor: 2.611

2.  Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter.

Authors:  Jennifer L Brockman; Linda A Schuler
Journal:  Mol Cell Endocrinol       Date:  2005-07-15       Impact factor: 4.102

3.  STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes.

Authors:  Qian Zhang; Hong Y Wang; Michal Marzec; Puthiyaveettil N Raghunath; Tomohiko Nagasawa; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-03       Impact factor: 11.205

4.  S731 in the transactivation domain modulates STAT5b activity.

Authors:  Amanda M Weaver; Corinne M Silva
Journal:  Biochem Biophys Res Commun       Date:  2007-08-28       Impact factor: 3.575

5.  Glucocorticoids and tumor necrosis factor alpha cooperatively regulate toll-like receptor 2 gene expression.

Authors:  Marcela A Hermoso; Tetsuya Matsuguchi; Kathleen Smoak; John A Cidlowski
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

6.  c-Src tyrosine kinase co-associates with and phosphorylates signal transducer and activator of transcription 5b which mediates the proliferation of normal human B lymphocytes.

Authors:  M-P Cayer; M Proulx; X-Z Ma; D Sakac; J-F Giguère; M Drouin; S Néron; D R Branch; D Jung
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

7.  STAT5 signaling is required for the efficient induction and maintenance of CML in mice.

Authors:  Dan Ye; Nicholas Wolff; Li Li; Shumin Zhang; Robert L Ilaria
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

Review 8.  Responses to Cytokines and Interferons that Depend upon JAKs and STATs.

Authors:  George R Stark; HyeonJoo Cheon; Yuxin Wang
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-01-02       Impact factor: 9.708

9.  The elements of human cyclin D1 promoter and regulation involved.

Authors:  Zhi-Yi Guo; Xiao-Hui Hao; Fei-Fei Tan; Xin Pei; Li-Mei Shang; Xue-Lian Jiang; Fang Yang
Journal:  Clin Epigenetics       Date:  2011-02-11       Impact factor: 6.551

10.  Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity.

Authors:  Sacha J Howell; Elizabeth Anderson; Tom Hunter; Gillian Farnie; Robert B Clarke
Journal:  Breast Cancer Res       Date:  2008-08-05       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.